注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Carisma Therapeutics Inc(原名:Sesen Bio Inc)是一家临床阶段的生物制药公司。该公司专注于为癌症和其他严重疾病患者发现和开发免疫疗法。该公司平台专注于工程巨噬细胞,即在先天性和适应性免疫反应中发挥作用的细胞。该公司产品线包括多种嵌合抗原受体巨噬细胞,旨在通过改造患者自身的免疫细胞来靶向实体瘤。其技术利用巨噬细胞生物学、嵌合抗原受体工程和细胞疗法的进步来治疗人类疾病。该公司的管线包括CT-0508、CT-0525、CT-1119和CT-0729。其CT-0508和CT-0525是一种体外基因修饰的自体嵌合抗原受体-巨噬细胞细胞疗法,用于治疗过度表达人表皮生长因子受体2(HER2)转移的实体瘤。其CT-1119是一种体外基因修饰的自体嵌合抗原受体-巨噬细胞细胞疗法。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Steven Kelly | 58 | 2023 | President, CEO & Director |
Sanford S. Zweifach | 67 | 2023 | Independent Chairman of the Board |
Regina Hodits | 55 | 2023 | Independent Director |
Nina Bhardwaj | - | 2020 | Member of Scientific Advisory Board |
Briggs W. Morrison | 64 | 2023 | Independent Director |
Padmanee Sharma | - | 2023 | Member of Scientific Advisory Board |
Carl H. June | 70 | - | Member of Scientific Advisory Board |
Lisa M. Coussens | - | - | Member of Scientific Advisory Board |
Saar Gill | - | - | Co-Founder & Chairman of Scientific Advisory Board |
Prasad S. Adusumilli | - | 2020 | Member of Scientific Advisory Board |
Michael Patrick Torok | 45 | 2023 | Independent Director |
Björn Odlander | 66 | 2023 | Independent Director |
Hyam I. Levitsky | 66 | - | Member of Scientific Advisory Board |
Lin Guey | - | 2023 | Member of Scientific Advisory Board |
John A. Hohneker | 64 | 2024 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核